97 results about "Bacillus fragilis" patented technology

The invention provides isolated polypeptide and nucleic acid sequences derived from Bacteroides fragilis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to application of bacteroides fragilis in preparation of a composition for treating inflammatory bowel diseases. The experiments show that bacteroides fragilis is safe and nontoxic and strong in pharmacologic action, and has good treating effect of treating inflammatory bowel diseases, thereby indicating that the bacteroides fragilis has good edible and medicinal prospects. According to the invention, a novel use of bacteroides fragilis is explored and a novel application field is developed. Bacteroides fragilis as a probiotic can be used for preparing foods or medical compositions for treating inflammatory bowel diseases so as to provide health-cared foods or treating medicines suitable for human body to take.

The invention provides an application of bacteroides fragilis ZY-312 to prevention and/or treatment of inflammatory bowel diseases (IBDs), including an application of bacteroides fragilis ZY-312 to preparation of medicines, medicine compositions, food, health care products, food additives, and the like for preventing and/or treating IBDs. In vivo and in vitro related experiments confirm that bacteroides fragilis ZY-312 has excellent resistance to the IBD, including ulcerative colitis or the Crohn's disease, does not have toxic or side effect and can be permanently and effectively applied to preparation of the medicines, medicine compositions, food, health care products or food additives for preventing and/or treating IBDs. The medicines, medicine compositions, food, health care products or food additives can be used for preventing and treating IBDs and have important application values.

The invention discloses a biomarker capable of detecting diseases. The biomarker at least comprises one of the following microbes or the combination of the following microbes: Akkermansia muciniphila, Bacteroides fragilis, Clostridium bolteae, Clostridium hathewayi, Clostridium sp.HGF2, Clostridium symbiosum, Eubacterium limosum, Lactobacillus fermentum, Lactobacillus salivarius, Ruminococcus torques, Streptococcus anginosus, Streptococcus infantis, Bacteroides stercoris, Bacteroides uniformis, Bilophila wadsworthia and Clostridiales sp.SS3/4. The invention further discloses an application of the biomarker for determining inflammatory bowel diseases. The invention also discloses a method, a system and a kit for detecting the biomarker in a tested object. According to the invention, through the research on intestinal flora, and through the high-throughput genome sequencing, the biomarker with high relativity with the inflammatory bowel diseases is screened out, and then the biomarker is utilized for accurately and efficiently detecting and diagnosing the inflammatory bowel diseases, and further used for monitoring the treatment effect for the disease.

The subject matter of the present invention is a bacteria or mix of bacteria having an antagonistic activity with respect to stains of S. aureus, P. aeruginosa, Streptococcus pyogenes, Enterococcus faecium, Enterobacter cloacae, Proteus mirabilis, Bacteroides fragilis Staphylococcus epidermidis, Propionibacterium acnes, Candida albicans and/or Malassezia furfur as well as the use thereof in the treatment and/or prevention of infections or colonisations related to those pathogens. The invention pertains to care products containing one or more non-pathogenic antagonistic strains intended to prevent and/or treat infections or colonisations on skin, wounds, mucous membranes and appendages.

The present invention relates to nucleic acid and amino acid sequences from Akkermansia muciniphila and from Bacteroides fragilis, coding for/representing novel alpha-1,3-fucosyltransferases. The invention also provides uses and methods for using the alpha-1,3-fucosyltransferases to generate fucosylated products, such as oligosaccharides, (glyco)proteins, or (glyco)lipids, in particular of 3-fucosyllactose.

The invention relates to a soil remediation agent. The soil remediation agent is prepared from the following components in parts by weight: 6 to 15 parts of photosynthetic bacteria, 10 to 12 parts of lactic acid bacteria, 2 to 7 parts of bacillus subtilis, 12 to 24 parts of actinomycetes, 0 to 2 parts of bacteroides fragilis, 3 to 5 parts of candida utilis, 0 to 3 parts of clostridium botlinum, 9 to 16 parts of nodule bacteria, 2 to 6 parts of thiobacillus, 4 to 14 parts of aspergillus niger, 13 to 26 parts of bacillus natto and 3 to 8 parts of thiobacillus; the strains are cultivated in respective culture mediums to form corresponding bacteria liquid. The soil remediation agent is also prepared from 7 to 11 parts of turfy soil and 1 to 5 parts of vermiculite. The soil remediation agent has insecticidal and fungicidal effects; according to the soil remediation agent, the fertilizer efficiency of soil can be improved, pests inside the soil and on the surface of the soil can be killed, the decomposition capacity of the soil is improved, organic matters are decomposed out, the remediation efficiency of the soil is high, the growing environment of crops is improved, and the yield is increased.

The invention discloses an alpha-galactosidase and an expression and purification method thereof. The alpha-galactosidase is expressed by SEQ ID NO:1 in a sequence table, is obtained by encoding a recombinant genome DNA sequence SEQ ID NO:3 of bacteroides fragilis (Bacteroides fragilis) ATCC25285 and is a protein with effect of converting a red cell blood group of the human body from B-type into O-type and from AB-type into A-type. The alpha-galactosidase of the invention has the advantages of wide application, simple and convenient expression and purification method, low cost, important clinical and scientific research significance and wide market prospect.

The invention discloses bacteroides fragilis capable of regulating and controlling relative abundance of akkermansia in intestinal tracts, and belongs to the technical field of microorganisms. The bacteroides fragilis CCFM1123 is screened out, and the bacteroides fragilis CCFM1123 has the effect of relieving inflammation. Specifically, the relative abundance of lactobacillus and akkermansia in theintestinal tract of an inflammatory mouse is remarkably improved; the content of proinflammatory factors TNF-alpha and IL-6 in the serum of the inflammatory mouse is remarkably reduced; intestinal inflammatory cell infiltration and mucosal bleeding caused by inflammatory response of the inflammatory mouse are remarkably reduced; and production of short-chain fatty acids in the intestinal tract ofthe inflammatory mice is obviously promoted. Therefore, the bacteroides fragilis CCFM1123 has a huge application prospect in preparation of products (such as foods or medicines) for preventing and/ortreating inflammation.

The invention belongs to the biotechnical field of foods, and concretely discloses a preparation method of fermented wheat germs. The preparation method comprises the following steps: 1, selecting high quality wheat, germinating the wheat, and keeping the water content unchanged in a range of 45-55% after malts just germinate; 2, inoculating aroma-producing yeast and BF839 Bacteroides fragilis, carrying out aerobic fermentation, inoculating bifidobacteria after fermentation is carried out for a certain time, filing a closed container with the obtained wheat, and carrying out anaerobic fermentation; 3, carrying out low temperature drying after fermentation ends; 4, degerming the dried wheat; and 5, adding sweet potato powder and high fructose syrup to degermed wheat germs, and puffing or baking to obtain the fermented wheat germs. Germinated wheat is fermented, degermed and post-processed to obtain the fermented wheat germs. The fermented wheat germs obtained in the invention contain abundant nutrients, contain aroma substances specially possessed by wheat, also have the baked sweet potato flavor, and has abundant nutrition values and unique flavor.

The invention relates to application of bacteroides fragilis to preparation of an enhancing agent for enhancing an intestinal mucosal barrier function. According to a great quantity of experiments, the bacteroides fragilis has functions of repairing intestinal epithelium mucus barrier and reducing intestinal mucosal permeability and is capable of effectively enhancing the intestinal mucosal barrier function to protect human health.

The invention provides a crystal form of (s)-ornidazole phosphate disodium, and a preparation method for the crystal form of the (s)-ornidazole phosphate disodium. In addition, pharmaceutical compositions containing the crystal form of the (s)-ornidazole phosphate disodium are applied in treatment of a plurality of infectious diseases caused by sensitive anaerobic bacteria like bacteroides fragilis, bacteroides distasonis, bacteroides ovatus, bacteroides thetaiotaomicron, bacteroides vulgatus, clostridium colinum, eubacterium, peptococcus and peptostreptococcus, helicobacter pylori, bacteroides melaninogenicus, fusobacterium, capnocytophaga and bacteroides gingivalis.

The invention brings forward biomarkers for end-stage renal disease and an application thereof. The biomarkers for end-stage renal disease are Akkermansia muciniphila, Alistipes finegoldii, Alistipesshahii, Bacteroides fibrobacter, Bacteroides fragilis, Bifidobacterium dentium, Clostridium difficile, Clostridium saccharolyticum, Desulfovibrio Vulgaris, Eggerthella lenta, Enterococcus faecalis, Enterococcus faecium, Flavonifractor plautii, Fusobacterium nucleatum, butyric acid-producing enterobacteriaceae, Lactobacillus amylovorus, Lactobacillus casei, Lactobacillus fermentum, Lactobacillus plantarum, Streptococcus infantarius, Streptococcus thermophilus, butyrate-producing bacteria, Eubacterium rectal and Faecalibacterium prausnitzi. Whether a subject suffers from or is susceptible to end-stage renal disease can be effectively determined by determining these microbial markers in the intestinal flora of the subject.

The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to application of bacteroides fragilis in preparing a composition for preventing and treating hypercholesteremia. Experiments show that bacteroides fragilis is safe, nontoxic and strong in pharmacologic action and has good preventing and treating effect to hypercholesteremia, thereby indicating that the bacteroides fragilis has good edible and officinal prospects. The invention explores novel use of bacteroides fragilis and develops a novel application field. Bacteroides fragilis as probiotic can be used for preparing foods or medical compositions for preventing and treating hypercholesteremia so as to provide a clinically health-care and preventing and treating food suitable for human to take.

The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to an application of bacteroides fragilis in preparation of compositions for preventing intestinal diseases of animals. The invention explores a novel use of bacteroides fragilis and opens up a novel application field. Experiments show that bacteroides fragilis as a kind of probiotics can be used for preparing animal feed additives to prevent intestinal diseases of animals so as to promote healthy growth of animals.

The present invention relates to agents and compositions for the modification of the growth of bacterial cells. Thus, the compounds of the present invention are useful for the prevention and/or treatment of a disease in a subject. In particular, the present invention relates to the field of repurposing pharmaceutical compounds for treatment strategies of infectious diseases, gastrointestinal disorders, inflammatory diseases, proliferative diseases, metabolic disorders, cardiovascular diseases, and immunological diseases. Some of the compounds of the present invention demonstrate high specificity in inhibiting the growth of single bacterial species. Such compounds enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development strategies in order to reduce side effects of antibacterial treatment plans. Particularly interesting compounds of this invention are effective against pathobiological species such as Clostridium difficile, Clostridium perfingens, Fusobacterium nucleatum, and an enterotoxigenic strain of Bacteroides fragilis. Other compounds of the present invention reveal a strong inhibitory effect on a broad spectrum of bacterial species. Such compounds are useful for broad-spectrum antibiotic therapies of infections with unknown causative infecting bacterial species. Both types of compounds, especially the ones with narrow-spectrum antibacterialactivity, can further be used for modulating the microbiome composition and targeting species associated with dysbiosis and disease.

The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to application of bacteroides fragilis in preparation of a composition for treating bacterial vaginitis. The experiments show that bacteroides fragilis is safe and nontoxic and strong in pharmacologic action, and has good treating effect to treat bacterial vaginitis, thereby indicating that the bacteroides fragilis has good edible and medicinal prospects. According to the invention, a novel use of bacteroides fragilis is explored and a novel application field is developed. Bacteroides fragilis as a probiotic can be used for preparing foods or medical compositions for treating bacterial vaginitis.

The invention provides a liquid-solid combined fermentation process for Bacteroides fragilis. The process comprises a first step of preparing a liquid nutrient solution from, by weight, 0.5 to 2.5% of peptone, 0.2 to 0.5% of glucose, 0.001 to 0.5% of cysteine, 0.2 to 0.5% of NaCl, 0.1 to 0.3% of NaHPO4, 0.02 to 0.1% of sodium thioglycolate, 30 to 60% of liquid ox liver extract, 30 to 60% of liquid beef extract and 0.1 to 0.8% of yeast extract. The process provided by the invention employs liquid-solid combined fermentation, and a great amount of Bacteroides fragilis can be obtained in a short period of time by using the process; and the process has the advantages of easiness, small investment, easy controllability in operation, small possibility of infection with competitors due to implementation of all the operations under vacuum and aseptic conditions and high concentration of bacterial strains.

The invention relates to a compound amoxicillin breast injectant prescription and a preparation method thereof. The compound amoxicillin breast injectant prescription comprises a suspending aid, an antioxidant and a solid dispersion carrier which are prepared through a special process to obtain white to off-white oily suspension. The compound amoxicillin breast injectant prescription disclosed by the invention has the advantages of simple preparation process, stable content, easy injection and the like. The composition disclosed by the invention is compounded from amoxicillin, clavulanate potassium and prednisolone; compared with other amoxicillin patent preparations, the composition has drug-tolerant bacteria for penicillins, and also has a high inhibition effect on the chromosome exzymes generated by klebsiella peneumoniae, bacillus proteus vulgaris and bacteroides fragilis; prednisolone has anti-inflammatory and antiallergic functions, and has a synergistic effect on bacterial infection and allergic inflammation.

The invention relates to application of bacteroides fragilis extract to preparation of medicines or foods for prevention and treatment of an irritable bowel syndrome. The bacteroides fragilis extractcontains bacteroides fragilis capsular polysaccharide A. Accidentally, the bacteroides fragilis capsular polysaccharide A with the molecular weight of 5-70KD is prepared, a great irritable bowel syndrome prevention and treatment function of the bacteroides fragilis capsular polysaccharide A with the molecular weight of 5-70KD is discovered, and the bacteroides fragilis capsular polysaccharide A with the molecular weight of 5-70KD is much more effective than capsular polysaccharide A, with the molecular weight of 110KD, extracted from bacteroides fragilis NCTC 9343.